Trial Profile
An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 02 Feb 2024
Price :
$35
*
At a glance
- Drugs Zanubrutinib (Primary) ; Bendamustine; Rituximab; Venetoclax
- Indications Chronic lymphocytic leukaemia
- Focus Registrational; Therapeutic Use
- Acronyms SEQUOIA
- Sponsors BeiGene
- 31 Jan 2024 According to a BeiGene media release, based on the results from SEQUOIA and ALPINE trials, the Governments of Ontario and Quebec have publicly listed BRUKINSA (zanubrutinib), for the treatment of adults living with chronic lymphocytic leukemia (CLL), The Regie de l'assurance maladie du Quebec listing came into effect December 13, 2023, and the Ontario Drug Benefit Program (ODB) added BRUKINSA on January 12, 2024.
- 12 Dec 2023 Results of a biomarker sub-group analysis assessing PFS in both treatment arms in patients sub grouped based on various biomarkers, including several known negative prognostic factors for CLL presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 15 Jun 2023 Results presented at the 28th Congress of the European Haematology Association